Bio News
Genentech will pay China-based DualityBio an upfront payment of $45 million (approximately 62.1 billion won). DualityBio will develop an antibody-drug conjugate (ADC) that delivers a DuPaс payload to targets selected by Genentech. Genentech will assume sole responsibility for development after Phase 1a, and the total value of the agreement, including milestones, is more than $1 billion (approximately 1.38 trillion won).
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
